TWST · Twist Bioscience Corp
$88.62
+2.08 (+2.40%)
At close · Jul 28
Market Cap
$5.39B
Shares
62.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$86.54
Open$93.50
Day$85.00–95.31
52W$23.30–105.47
Avg vol 30d1.8M
Short int14.1M · 22.7% float · 9.7d
Short vol40%
Last earningsAug 3, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 4
Up next
Next earnings call
Aug 3, 2026
Scheduled
· in 1 wks
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed May 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+69%
above
Price vs 50-day avg
+9%
above
RSI (14)
47
neutral
MACD trend
Negative
52-week position
77%
mid-range
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+111%
trailing
YTD return
+173%
this year
Relative strength
+104%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $80 › 200d $51 — 50d above 200d
Institutional flow
Distributing
57 of 281 funds reported for Jun 30 · net -70.3K sh shares · +14 new
Insider flow
Distributing
Net -$11.5M over 90 days · 100% sells
Short interest
Rising
22.67% of float · ▲ +1.2% MoM · 9.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
281 holders — near 3-yr high, broad support
Squeeze score
91
high risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+64%
Y/Y
Free cash flow
$-75.6M
Balance sheet
$181.6M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 4, 2026
full fiscal year 2026
Total revenue
Initiated
$442M – $447M
prior FY $376.57M
midpoint +18.0% Y/Y
third quarter
Total revenue
Initiated
$114M – $115M
prior qtr $110.72M
midpoint +3.4% QoQ
fourth quarter of fiscal 2026
Adjusted EBITDA
Non-GAAP
Initiated
$0
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+69%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
77%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $80 › 200d $51 — 50d above 200d
Institutional flow
Distributing
57 of 281 funds reported for Jun 30 · net -70.3K sh shares · +14 new
Insider flow
Distributing
Net -$11.5M over 90 days · 100% sells
Short interest
Rising
22.67% of float · ▲ +1.2% MoM · 9.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
281 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $23
Now $87 · 77%
52-wk high $105
vs 200-day avg +69%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$13.3M | Q2 FY2026 | — |
|
|
|||
| Customers shipped to | 2,583 | Q2 FY2026 | — |
|
|
|||
| Genes physically shipped | 300,000 | Q2 FY2026 | — |
|
|
|||
| Cash, cash equivalents and short-term investments | $198M | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TWST
this stock
Twist Bioscience Corp
|
$5.39B | +172.8% | +20.3% | — | 22.7% |
|
TMO
Thermo Fisher Scientific Inc.
|
$207.93B | -3.3% | +0.4% | 30.8 | 1.4% |
|
DHR
Danaher Corp /De/
|
$138.14B | -13.8% | +8.5% | 34.8 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.93B | -17.8% | +10.4% | 41.9 | 2.7% |
|
IQV
Iqvia Holdings Inc.
|
$40.55B | -5.4% | +41.6% | 26.5 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TWST | -7.8% | -10.5% | +110.7% | -15.9% | +172.8% |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | -7.2% | -11.1% | +103.9% | -14.9% | +164.4% |
Key facts
CIK
1581280
CUSIP
90184D100
13F (30d)
77 filings
53 filers
Visit website
Investor relations